MNK1/2 protein kinase inhibitors (Novartis Institutes for BioMedical Research)

N/A

Report date: 2025/03/20 16:02:29

NME

Base Information

Drug NameMNK1/2 protein kinase inhibitors (Novartis Institutes for BioMedical Research)

Drug Alias NameN/A

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionMAP kinase-interacting serine/threonine-protein kinase MNK1 inhibitorsMAP kinase-interacting serine/threonine-protein kinase 2 inhibitors

TargetsMAP kinase-interacting serine/threonine-protein kinase 2MAP kinase-interacting serine/threonine-protein kinase MNK1

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesNovartis Institutes For Biomedical Research Inc

China Registration ClassN/A

Develop Information

Active CompaniesNovartis Institutes For Biomedical Research Inc

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A